Ivonescimab Gains Priority Review for Biliary Cancer
China's regulator has granted priority review to a combination therapy that also met its primary survival endpoint in a Phase III trial.
Updated on Nov. 5, 2026 in Cancer
China's National Medical Products Administration granted Priority Review to ivonescimab plus chemotherapy for first-line biliary tract cancer, developed by Akeso. Akeso's Phase III HARMONi-GI1 trial met its primary overall survival endpoint against durvalumab plus chemotherapy.
Why it matters
Priority Review is expected to accelerate regulatory review in China, and the positive overall survival result offers a potential new option for a cancer with limited first-line treatments. The drug's global ambitions are supported by Summit Therapeutics' licensing rights outside China.
The HARMONi-GI1 Phase III trial randomized patients to ivonescimab plus chemotherapy or durvalumab plus chemotherapy and met its primary overall survival endpoint at a prespecified interim analysis reviewed by an Independent Data Monitoring Committee. The source does not disclose the size of the survival difference or the trial's full enrollment, and final regulatory outcomes remain pending.
The players
Akeso
Akeso is a Hong Kong-based biopharmaceutical company developing a pipeline of more than 50 innovative assets, with eight drugs commercially available.
Summit Therapeutics
Summit Therapeutics is a biotechnology company that licensed ivonescimab rights outside China under an agreement with a total potential value of up to US$5 billion.
ECOG-ACRIN Cancer Research Group
ECOG-ACRIN Cancer Research Group is a National Cancer Institute-supported cooperative oncology research organization that conducts clinical trials across the United States.
The details
The trial was randomized, double-blind and multicenter, and results were presented as a Late-Breaking Abstract at the ESMO Presidential Symposium in October 2026. The trial also met all key secondary endpoints, including progression-free survival and objective response rate.
Timeline
October 2026: HARMONi-GI1 results presented at the ESMO Presidential Symposium.
October 21, 2026: Summit Therapeutics announced a clinical trial collaboration with ECOG-ACRIN Cancer Research Group.
November 5, 2026: Akeso announced the NMPA Priority Review grant.
Health Landscape
Ivonescimab is being tested head-to-head against PD-1/PD-L1 therapies in seven studies and is part of more than 17 Phase III programs worldwide. The biliary cancer result positions it directly against durvalumab plus chemotherapy, a standard first-line regimen that the trial used as its comparator.
For patients with biliary tract cancer, a combination therapy that improves overall survival could eventually offer a new first-line option, though availability depends on regulatory approval and local reimbursement. Patients and clinicians should follow the outcome of China's Priority Review and any subsequent approvals in other markets.
The takeaway
Priority Review signals regulatory momentum for ivonescimab, but patients should await approval and clinical guidance before expecting access. Tracking trial results and regulatory decisions in each region will clarify when this option may reach routine care.
Further reading
Explore more on Cancer treatment developments and clinical trial news.
